



EXPRESS MAIL NO. EV718246255US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Dean Pettit and Claudia M. Jochheim
Application No. : 09/800,016
Filed : March 5, 2001
For : USE OF EDTA IN STABILIZING GRANULOCYTE
MACROPHAGE COLONY-STIMULATING FACTOR (As
Amended)

Examiner : Lorraine Spector, Ph.D.
Art Unit : 1647
Docket No. : 140145.410
Date : August 18, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 C.F.R. § 1.98, are enclosed). As to the references supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate said references, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

We hereby certify that the items set forth on the attached form PTO-1449 were not first cited in a communication from a foreign patent office in a counterpart foreign application and, to our knowledge, after making reasonable inquiry, was known to any individual



designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Please acknowledge receipt of this Fifth Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

A fee of \$180 is submitted in accordance with 37 C.F.R. § 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Qing Lin, Ph.D.
Registration No. 53,937

Enclosures:

Form PTO-1449
Cited References (X 4)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

(QXL:jjf) 681276_1.DOC



EXPRESS MAIL NO. EV718246255US Sheet 1 of 1

FORM PTO-1489 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 140145.410		APPLICATION NO. 09/800,016	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Dean Pettit and Claudia M. Jochheim			
				FILING DATE March 5, 2001		GROUP ART UNIT 1647	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AI						
	AJ						
	AK						
	AL						
	AM						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AN	Ruiz, L. et al., "Long-term stabilization of recombinant human interferon α 2b in aqueous solution without serum albumin," <i>International Journal of Pharmaceutics</i> , 264(1-2):57-72, October 2, 2003.					
	AO	Thavas, P. W. et al., "Measuring cytokine levels in blood: Importance of anticoagulants, processing, and storage conditions," <i>Journal of Immunological Methods</i> , 153:115-124, 1992.					
	AP	Tsai, P. K. et al., "Formulation Design of Acidic Fibroblast Growth Factor," <i>Pharmaceutical Research</i> , 10(5):649-659, May 1993.					
	AQ	Wang, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <i>International Journal of Pharmaceutics</i> , 185(2):129-188, August 20, 1999.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							